首页> 美国卫生研究院文献>Cancer Science >Infiltration of tumor‐associated macrophages is involved in tumor programmed death‐ligand 1 expression in early lung adenocarcinoma
【2h】

Infiltration of tumor‐associated macrophages is involved in tumor programmed death‐ligand 1 expression in early lung adenocarcinoma

机译:肿瘤相关巨噬细胞的浸润与早期肺腺癌中肿瘤程序性死亡配体1的表达有关。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Programmed death‐ligand 1 (PD‐L1) is an immune modulator that promotes immunosuppression by binding to programmed death‐1 of T‐lymphocytes. Although tumor cell PD‐L1 expression has been shown to be associated with the clinical response to anti–PD‐L1 antibodies, its concise regulatory mechanisms remain elusive. In this study, we evaluated the associations of tumor PD‐L1 expression and immune cell infiltrating patterns in 146 cases of early lung adenocarcinoma (AC) to investigate the possible extrinsic regulation of tumor PD‐L1 by immune cells. Using immunohistochemistry, cell surface PD‐L1 expression in tumor cells was observed in 18.5% of stage 0‐IA lung AC patients. Tumor PD‐L1 positivity was significantly associated with stromal invasion, which was accompanied by increased tumor‐associated macrophages (TAM), CD8 cytotoxic T cells and FoxP3 regulatory T cells. Among these immune cells, TAM and CD8 T cells significantly accumulated in PD‐L1‐positive carcinoma cell areas, which showed a tumor cell nest‐infiltrating pattern. Although CD8 T cells are known to induce tumor PD‐L1 expression via interferon‐ɣ production, the increased TAM within tumors were also associated with tumor cell PD‐L1 positivity, independently of CD8 T cell infiltration. Our in vitro experiments revealed that PD‐L1 expression in lung cancer cell lines was significantly upregulated by co–culture with M2‐differentiated macrophages; expression of PD‐L1 was reduced to baseline levels following treatment with a transforming growth factor‐β inhibitor. These results demonstrated that tumor‐infiltrating TAM are extrinsic regulators of tumor PD‐L1 expression, indicating that combination therapy targeting both tumor PD‐L1 and stromal TAM might be a possible strategy for effective treatment of lung cancer.
机译:程序性死亡配体1(PD-L1)是一种免疫调节剂,通过与T淋巴细胞的程序性死亡-1结合来促进免疫抑制。尽管已显示肿瘤细胞PD-L1的表达与抗PD-L1抗体的临床反应有关,但其简洁的调节机制仍然难以捉摸。在这项研究中,我们评估了146例早期肺腺癌(AC)中肿瘤PD-L1表达与免疫细胞浸润模式之间的关系,以研究免疫细胞对肿瘤PD-L1的外在调节。使用免疫组织化学,在18.5%的0-IA期肺部AC患者中观察到肿瘤细胞中细胞表面PD-L1的表达。肿瘤PD‐L1阳性与基质浸润显着相关,并伴有肿瘤相关巨噬细胞(TAM),CD8细胞毒性T细胞和FoxP3调节性T细胞增加。在这些免疫细胞中,TAM和CD8 T细胞大量聚集在PD-L1阳性癌细胞区域,表现出肿瘤细胞巢状浸润模式。尽管已知CD8 T细胞可通过干扰素的产生诱导肿瘤PD-1 L的表达,但肿瘤内TAM的增加也与肿瘤细胞PD L1的阳性有关,而与CD8 T细胞的浸润无关。我们的体外实验表明,与M2分化的巨噬细胞共培养时,肺癌细胞系中PD-1 L1的表达显着上调。用转化生长因子-β抑制剂治疗后,PD-L1的表达降至基线水平。这些结果表明,肿瘤浸润性TAM是肿瘤PD-L1表达的外在调节剂,表明针对肿瘤PD-L1和基质TAM的联合治疗可能是有效治疗肺癌的可能策略。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号